Biogen Idec Seeks Oncology Pipeline Boost Through Acquisition

Merger with Conforma Therapeutics, valued at up to $250 mil., brings Biogen Idec a stable of developmental heat shock protein inhibitors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet